highly significantP = 0.015
However, in patients with GS 2–6 tumors, short-course HT administered before and during RT resulted in a highly significant improvement in OS (70% vs 52%, P = 0.015). 39 An interesting analysis combining the RTOG 85-31 and RTOG 86-10 trials was performed by Horwitz et al. 40 According to this study, the statistically significant benefit in bNED control ( P = 0.0002), DMF ( P = 0.05), and CSF ( P = 0.02) in patients receiving long-term HT was limited to centrally reviewed GS 7 and 8–10 tumors.